NLS Pharmaceutics Ltd. financial data

Symbol
NLSP, NLSPW on Nasdaq
Location
The Circle 6, 8058, Zurich, Switzerland
State of incorporation
Switzerland
Fiscal year end
December 31
Latest financial report
20-F - Q4 2023 - May 15, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 35.7M shares +10%
Common Stock, Shares, Outstanding 986K shares -97.2%
Common Stock, Value, Issued 809K USD +10.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 553K USD -66.5%
Assets, Current 1.19M USD -46.9%
Property, Plant and Equipment, Net 990 USD -92%
Other Assets, Noncurrent 16.9K USD +39.1%
Assets 1.19M USD -47.4%
Accounts Payable, Current 4.58M USD +47.3%
Accrued Liabilities, Current 1.65M USD +67.5%
Liabilities, Current 7.72M USD +98.3%
Contract with Customer, Liability, Noncurrent 2.5M USD
Liabilities 10.5M USD +59.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 4.21K USD
Retained Earnings (Accumulated Deficit) -72.4M USD -10%
Stockholders' Equity Attributable to Parent -9.27M USD -116%
Liabilities and Equity 1.19M USD -47.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 35.7M shares +21.6%
Common Stock, Shares, Issued 986K shares -97.2%
Common Stock, Par or Stated Value Per Share 0.02 CHF/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 553K USD -66.5%
Deferred Tax Assets, Valuation Allowance 4.6M USD +22.7%
Deferred Tax Assets, Gross 1M USD -10.3%
Property, Plant and Equipment, Gross 39.6K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 4.34M USD +24.5%
Additional Paid in Capital 61M USD +0.27%